In addition to injecting expanded activated NK cells, which can combine the characteristics of different immune cells to improve the advantages of immunotherapy, CTLs target cancer cells expressing a major histocompatibility complex (MHC), and NK cells also fight against cells that do not express MHC, such that the antigen-stimulated peptide-pulsed DCs can activate CTLs. The gene discussed is HLA-C; the disease is cancer.